Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Mirum Pharmaceuticals, Inc. (MIRM)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| | 8-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | | |
| Cost of goods sold | 0.0% | 0.0% | | |
| Gross profit | 100.0% | 100.0% | | |
| Selling, general and administrative | 115.6% | 1006.1% | | |
| Research and development | | 686.7% | | |
| EBITDA | -170.3% | -903.0% | | |
| Depreciation | | 3.1% | | |
| EBIT | -170.3% | -906.1% | | |
| Pre-tax income | -184.4% | -438.7% | | |
| Income taxes | -8.3% | 0.2% | | |
| Net income | -176.0% | -438.9% | | |
|